BACKGROUND: The atypical protein kinase C lambda/iota (aPKClambda/iota) is involved in several signal transduction pathways that influence cell growth, apoptosis, and the establishment and maintenance of epithelial cell polarity. Overexpression of aPKClambda/iota has been reported in several cancers and been shown to be associated with oncogenesis. However, the expression and role of aPKClambda/iota in gastric cancer, one of the commonest cancers in Asia, have not so far been investigated. This study aimed to clarify the relationship between aPKClambda/iota expression and the clinicopathological features of gastric cancer. PATIENTS AND METHODS: Gastric adenocarcinoma samples were obtained from 177 patients who underwent gastrectomy at the Yokohama City University Hospital between 1999 and 2004. Expression of aPKClambda/iota and E: -cadherin was examined immunohistochemically and compared with clinicopathological features of the tumors. Univariate and multivariate analyses were performed for both disease-specific and relapse-free survival. RESULTS: Overexpression of aPKClambda/iota protein was detected in 126 of the 177 (71.2%) gastric cancers. Immunohistological staining for aPKClambda/iota was stronger in gastric adenocarcinoma of intestinal type than diffuse type (p = 0.036), but was not correlated with E: -cadherin expression. A multivariate analysis suggested that nodal metastasis and aPKClambda/iota overexpression were prognostic factors for disease recurrence. CONCLUSIONS: Our results suggested that aPKClambda/iota overexpression was a strong prognostic factor for gastric adenocarcinoma recurrence. As well as being a new prognostic indicator, aPKClambda/iota is also likely to be a novel therapeutic target for gastric cancer.
BACKGROUND: The atypical protein kinase C lambda/iota (aPKClambda/iota) is involved in several signal transduction pathways that influence cell growth, apoptosis, and the establishment and maintenance of epithelial cell polarity. Overexpression of aPKClambda/iota has been reported in several cancers and been shown to be associated with oncogenesis. However, the expression and role of aPKClambda/iota in gastric cancer, one of the commonest cancers in Asia, have not so far been investigated. This study aimed to clarify the relationship between aPKClambda/iota expression and the clinicopathological features of gastric cancer. PATIENTS AND METHODS: Gastric adenocarcinoma samples were obtained from 177 patients who underwent gastrectomy at the Yokohama City University Hospital between 1999 and 2004. Expression of aPKClambda/iota and E: -cadherin was examined immunohistochemically and compared with clinicopathological features of the tumors. Univariate and multivariate analyses were performed for both disease-specific and relapse-free survival. RESULTS: Overexpression of aPKClambda/iota protein was detected in 126 of the 177 (71.2%) gastric cancers. Immunohistological staining for aPKClambda/iota was stronger in gastric adenocarcinoma of intestinal type than diffuse type (p = 0.036), but was not correlated with E: -cadherin expression. A multivariate analysis suggested that nodal metastasis and aPKClambda/iota overexpression were prognostic factors for disease recurrence. CONCLUSIONS: Our results suggested that aPKClambda/iota overexpression was a strong prognostic factor for gastric adenocarcinoma recurrence. As well as being a new prognostic indicator, aPKClambda/iota is also likely to be a novel therapeutic target for gastric cancer.
Authors: José M C Ribeiro; Fernando A Genta; Marcos H F Sorgine; Raquel Logullo; Rafael D Mesquita; Gabriela O Paiva-Silva; David Majerowicz; Marcelo Medeiros; Leonardo Koerich; Walter R Terra; Clélia Ferreira; André C Pimentel; Paulo M Bisch; Daniel C Leite; Michelle M P Diniz; João Lídio da S G V Junior; Manuela L Da Silva; Ricardo N Araujo; Ana Caroline P Gandara; Sébastien Brosson; Didier Salmon; Sabrina Bousbata; Natalia González-Caballero; Ariel Mariano Silber; Michele Alves-Bezerra; Katia C Gondim; Mário Alberto C Silva-Neto; Georgia C Atella; Helena Araujo; Felipe A Dias; Carla Polycarpo; Raquel J Vionette-Amaral; Patrícia Fampa; Ana Claudia A Melo; Aparecida S Tanaka; Carsten Balczun; José Henrique M Oliveira; Renata L S Gonçalves; Cristiano Lazoski; Rolando Rivera-Pomar; Luis Diambra; Günter A Schaub; Elói S Garcia; Patrícia Azambuja; Glória R C Braz; Pedro L Oliveira Journal: PLoS Negl Trop Dis Date: 2014-01-09
Authors: A Paul; S Gunewardena; S R Stecklein; B Saha; N Parelkar; M Danley; G Rajendran; P Home; S Ray; I Jokar; G A Vielhauer; R A Jensen; O Tawfik; S Paul Journal: Cell Death Differ Date: 2014-05-02 Impact factor: 15.828
Authors: Shraddha R Desai; Prajit P Pillai; Rekha S Patel; Andrea N McCray; Hla Y Win-Piazza; Mildred E Acevedo-Duncan Journal: Carcinogenesis Date: 2011-10-21 Impact factor: 4.944